Meeting
2022 ASCO Annual Meeting
Texture-based CT radiomics distinguishes radiation and immunotherapy induced pneumonitis in stage III NSCLC.
Authors
Lukas Delasos
Cleveland Clinic Foundation, Cleveland, OH
Lukas Delasos , Vidya Sankar Viswanathan , Mohammadhadi Khorrami , Khalid Jazieh , Nathan A. Pennell , Anant Madabhushi , Pradnya Dinkar Patil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8555)
DOI
10.1200/JCO.2022.40.16_suppl.8555
Abstract #
8555
Poster Bd #
182
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Timing of immunotherapy-induced pneumonitis in patients with primary lung malignancy.
First Author: Megan Winter
Poster
2021 ASCO Annual Meeting
Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab.
First Author: Khalid Jazieh
Poster
2023 ASCO Quality Care Symposium
Management and treatment of patients (pts) with stage III unresected non-small cell lung cancer (NSCLC) at UPMC: A quality initiative by Integra Connect PrecisionQ.
First Author: Daniel P. Petro
Poster
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
First Author: Jarushka Naidoo